{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T03:40:30Z","timestamp":1700624430372},"reference-count":28,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T00:00:00Z","timestamp":1233100800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:sec><jats:title>Background<\/jats:title><jats:p>The relationship between the subjective diagnosis of lipoatrophy and the objective amount of limb fat loss in HIV\u2010infected adults is unclear.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Using Medline, we identified published articles reporting the amount of arm, leg or limb fat measured by dual X\u2010ray absorptiometry in HIV\u2010infected patients with moderate\u2010severe lipoatrophy and in healthy non\u2010HIV\u2010infected adults. We calculated the relative content of fat in the limbs, arms and legs of lipoatrophic patients with regard to the weighted arithmetic means of those fat values in healthy controls.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We found 799 patients from 10 articles, and 73 healthy controls from two articles. Limb fat ranged from 2.6 to 4.4\u2003kg in patients, and from 7.1 to 7.2\u2003kg in controls. Both patients and controls were almost exclusively men, of white race, and in their forties. Weighted arithmetic means of arm, leg and limb fat in HIV\u2010infected patients with clinically evident lipoatrophy were 1.0, 2.1 and 3.1\u2003kg, respectively (48, 41 and 43% relative to healthy non\u2010HIV\u2010infected males, respectively).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>The diagnosis of lipoatrophy was highly correlated with the amount of limb fat, irrespective of the investigators. HIV\u2010infected men with clinically evident lipoatrophy had a limb fat loss of &gt;50% compared with non\u2010HIV\u2010infected healthy males.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2008.00680.x","type":"journal-article","created":{"date-parts":[[2009,1,28]],"date-time":"2009-01-28T03:27:20Z","timestamp":1233113240000},"page":"257-261","source":"Crossref","is-referenced-by-count":6,"title":["Objective amount of limb fat in HIV\u2010infected subjects with subjective diagnosis of lipoatrophy"],"prefix":"10.1111","volume":"10","author":[{"given":"E","family":"Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Larrousse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D","family":"Podzamczer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JM","family":"Gatell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,3,11]]},"reference":[{"key":"e_1_2_6_2_2","first-page":"247","article-title":"From lipodystrophy and insulin resistance to metabolic syndrome","volume":"2","author":"Capeau J.","year":"2007","journal-title":"HIV infection, treatment and aging"},{"key":"e_1_2_6_3_2","first-page":"726","article-title":"An objective case definition of lipodystrophy in HIV\u2010infected adults","volume":"361","author":"HIV Lipodystrophy Case Definition Study Group.","year":"2003","journal-title":"a case-control study"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200107270-00008"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1177\/135965350300800614"},{"key":"e_1_2_6_6_2","unstructured":"HaubrichRH RiddlerS the AIDS Clinical Trials Group 5142 Study Teamet al. Metabolic outcomes of ACTG 5142: a prospective randomized phase III trial of NRTI\u2010 PI\u2010 and NNRTI\u2010sparing regimens for initial treatment of HIV\u20101 infection.14th Conference on Retroviruses and Opportunistic Infections. Los Angeles CA February 2007 [Abstract 38]."},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1086\/589622"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1086\/507333"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-1293.2007.00534.x"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00005"},{"key":"e_1_2_6_11_2","first-page":"199","article-title":"Rosiglitazone in the treatment of HAART\u2010associated lipodystrophy","volume":"8","author":"Sutinen J","year":"2003","journal-title":"a randomized double-blind placebo-controlled study"},{"key":"e_1_2_6_12_2","first-page":"2489","article-title":"Thymidine analogue withdrawal for lipoatrophic patients on protease\u2010sparing therapy improves lipoatrophy but compromises antiviral control","volume":"16","author":"Smith DE","year":"2002","journal-title":"the PIILR Extension Study"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200501030-00002"},{"key":"e_1_2_6_14_2","first-page":"1029","article-title":"Reversibility of lipoatrophy in HIV\u2010infected patients 2 years after switching from a thymidine analogue to abacavir","volume":"18","author":"Martin A","year":"2004","journal-title":"the MITOX Extension Study"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.207"},{"key":"e_1_2_6_16_2","first-page":"429","article-title":"No effect of rosiglitazone for treatment of HIV\u20101 lipoatrophy","volume":"363","author":"Carr A","year":"2003","journal-title":"randomised, double-blind, placebo-controlled trial"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200305010-00004"},{"key":"e_1_2_6_18_2","first-page":"263","article-title":"Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodeficiency virus\u2010infected patients switched from stavudine to abacavir or zidovudine","volume":"38","author":"McComsey GA","year":"2004","journal-title":"the results of the TARHEEL Study"},{"key":"e_1_2_6_19_2","first-page":"786","article-title":"Metabolic effects of rosiglitazone in HIV lipodystrophy","volume":"140","author":"Hadigan C","year":"2004","journal-title":"a randomized, controlled trial"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000247574.33998.03"},{"key":"e_1_2_6_21_2","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1177\/135965350701200301","article-title":"The impact of reducing stavudine dose vs. switching to tenofovir on plasma lipids, body composition and mitochondrial function in HIV\u2010infected patients","volume":"12","author":"Milinkovic A","year":"2007","journal-title":"Antivir Ther"},{"key":"e_1_2_6_22_2","first-page":"97","article-title":"Uridine supplementation for the treatment of antiretroviral therapy\u2010associated lipoatrophy","volume":"12","author":"Sutinen J","year":"2007","journal-title":"a randomized, double-blind, placebo-controlled trial"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1086\/518005"},{"key":"e_1_2_6_24_2","first-page":"67","article-title":"Effect of pioglitazone on HIV\u20101\u2010related lipodystrophy","volume":"13","author":"Slama L","year":"2008","journal-title":"a randomized double blind placebo-controlled trial (ANRS 113)"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199807000-00003"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ajcn\/69.6.1162"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000182230.47819.aa"},{"key":"e_1_2_6_28_2","first-page":"139","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine","volume":"44","author":"Podzamczer D","year":"2007","journal-title":"96-week results of a randomized study"},{"key":"e_1_2_6_29_2","unstructured":"PodzamczerD FerrerE MartinezEet al. How much fat loss is needed for lipoatrophy to become clinically evident?15th Conference on Retroviruses and Opportunistic Infections Boston MA February 2008 [Abstract 941]."}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2008.00680.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2008.00680.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T15:24:27Z","timestamp":1696865067000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2008.00680.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3,11]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1111\/j.1468-1293.2008.00680.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2008.00680.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,3,11]]}}}